Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $559 million.

For earnings history and earnings-related data on Milestone Pharmaceuticals Inc. (MIST) click here.